Ad5-triCoV/Mac
/ McMaster University
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 12, 2025
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: McMaster University | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 15, 2024
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
(clinicaltrials.gov)
- P1 | N=36 | Active, not recruiting | Sponsor: McMaster University | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 23, 2024
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
(clinicaltrials.gov)
- P1 | N=30 | Active, not recruiting | Sponsor: McMaster University | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 03, 2023
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Dec 2023 ➔ Sep 2024
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4
October 12, 2022
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: McMaster University | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Sep 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4
1 to 5
Of
5
Go to page
1